INBRX-106 + Pembrolizumab
Phase 2/3Recruiting 0 watching 0 views this week📈 Rising
60
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Head and Neck Squamous Cell Carcinoma (HNSCC)
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Trial Timeline
May 14, 2024 → May 1, 2029
NCT ID
NCT06295731About INBRX-106 + Pembrolizumab
INBRX-106 + Pembrolizumab is a phase 2/3 stage product being developed by Inhibrx Biosciences for Head and Neck Squamous Cell Carcinoma (HNSCC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06295731. Target conditions include Head and Neck Squamous Cell Carcinoma (HNSCC).
Hype Score Breakdown
Clinical
22
Activity
15
Company
5
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06295731 | Phase 2/3 | Recruiting |
Competing Products
20 competing products in Head and Neck Squamous Cell Carcinoma (HNSCC)